Overview

Telitacicept for the Treatment of Refractory RA

Status:
NOT_YET_RECRUITING

Trial end date:
2026-01-01

Target enrollment:

Participant gender:

Summary

This is a single-center, single-arm, open-label, prospective study on the efficacy and safety of Telitacicept in patients with refractory rheumatoid arthritis.

Phase:

PHASE4

Details

Lead Sponsor:

Chinese SLE Treatment And Research Group

Treatments:

telitacicept